When 'temporary' isn't: what a 2026 meta-analysis says about loop ileostomies after rectal cancer surgery

Treatment for rectal cancer often involves surgery to remove the affected section of bowel, and that surgery can include an ileostomy — an opening (stoma) made in the abdomen so waste from the small intestine can collect into a pouch outside the body [1]. An ileostomy formed at the time of surgery can be planned as either permanent or temporary. A temporary one is created to divert waste away from a newly joined section of bowel while it heals, and the plan, from the start, is that it will be reversed in a later operation [2].

That word — temporary — does a lot of work in a pre-op conversation. It sets the expectation that the stoma is a stage, not a destination. And the honest question worth sitting with is: in real-world series of these operations, how often does that expectation actually hold?

A 2026 systematic review and meta-analysis in Colorectal Disease, the official journal of the Association of Coloproctology of Great Britain and Ireland, took that question on directly. It pooled 19 studies covering 9,932 patients who had restorative rectal cancer surgery with a defunctioning loop ileostomy, and estimated how often the stoma was still in place more than 12 months later — what the authors call a prolonged-permanent stoma, or PPS. The pooled estimate was 18.7% of patients (95% confidence interval 15.3% to 22.5%). The authors describe this as nearly one in five cases progressing to a prolonged-permanent stoma [3] [4].

It is worth being precise about the kind of evidence that produced that figure. All 19 included studies were retrospective — they looked back at existing patient records rather than following patients forward in a planned trial. The authors graded the certainty of the evidence on the individual risk-factor predictors using the GRADE framework, and that certainty ranged from very low to, at best, moderate for the single strongest predictor (tumour recurrence) [5]. This is the careful way to read a number like 18.7%: it is the best current pooled estimate from the literature available up to August 2025, drawn from observational data, not from randomised trials. It tells us something real about how often the temporary stoma did not get reversed in these cohorts — and it does not tell us what will happen for any individual patient.

The review went on to ask which patients were more likely to end up in that group. Of 17 candidate predictors examined, three stood out as the strongest single associations — each linked to roughly a fivefold increase in the risk of a prolonged-permanent stoma in the pooled analysis: local or systemic cancer recurrence, an anastomotic leak (a leak from the surgical join in the bowel), and stage IV disease (metastatic disease already detected at the time of diagnosis) [6]. Smaller but still statistically significant associations were reported for higher comorbidity and ASA score, open (rather than minimally invasive) surgery, having received neoadjuvant or adjuvant therapy, and postoperative complications — each with an odds ratio below 2 [7].

None of that is a way to predict, from a list, who will keep a stoma. These are associations reported across thousands of patients in retrospective records — meaningful at the population level, with the GRADE-noted uncertainty at the individual level. The authors themselves conclude that the identified risk factors should help inform care, and that more robust clinical studies are still needed [8].

So what is the useful takeaway here, written for someone who is reading this because they are about to have one of these operations, or because they already have? It isn't a number to be alarmed by, and it isn't a score card to apply to your own case. It's that the word temporary sits on top of a real range of outcomes — closer to four in five for reversal in these pooled series, but not all. The realistic posture is to hold both at once: planning, hopefully, on the reversal that the surgical team is planning on too — and asking, openly, what the team's experience suggests for your particular situation, what would change the plan, and what the follow-up looks like along the way. Your surgical and stoma care team know your case in a way no review can — that is the conversation worth having, and it is the one this kind of evidence is meant to support, not replace.